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a b s t r a c t
Xenotropic Murine leukemia virus-Related Virus (XMRV) directly arose from genetic recombinations
between two endogenous murine retroviruses that occurred during human xenografts in laboratory
mice. Studies on XMRV could thus bring clues on how a new retrovirus could circumvent barrier species.
We observed that XMRV exhibits a weak promoter activity in human cells, similar to the transcription
level of a Tat-defective HIV-1. Despite this low ﬁtness, XMRV can efﬁciently propagate through the huge
accumulation of viral copies (E40 copies per cell) that compensates for the low expression level of
individual proviruses. We further demonstrate that there is an inverse relationship between the
maximum number of viral copies per infected cell and the level of viral expression, which is explained
by viral envelope interference mechanisms. Low viral expression compensation by viral copy accumula-
tion through delayed interference could a priori contribute to the propagation of others viruses following
species jumps.
& 2014 Elsevier Inc. All rights reserved.
Introduction
The emergence of new viruses is often associated with interspecies
transmission coupled to mutational or recombination events required
to overcome species barriers limiting viral replication. The initial
founder virus is in most cases unknown, as it is believed to be quickly
overridden by genetic variants that are better ﬁtted to their new hosts.
This is unfortunate, as there is a real need for models to understand
the biological properties of the founder viruses and the adaptive
changes that are selected over time. Unintended spread of recombi-
nant retroviruses following xenografts and cell line cultures have
been described since the 1970s (Todaro et al., 1973; Achong et al.,
1976; Suzuki et al., 1977; McAllister et al., 1972) but regained interest
recently following the discovery of a new retrovirus, XMRV (Xeno-
tropic Murine leukemia virus-Related Virus), in human prostate tumor
tissues using a Virochip DNA array (Urisman et al., 2006). It was
recently shown that XMRV was generated by genetic recombination
between two murine endogenous retroviruses, PreXMRV1 and PreX
MRV2, during passaging of human CWR22 prostate cancer xenografts
(Paprotka et al., 2011). Recombination between these proviruses has
been reproduced in vitro, generating multiple replication-competent
retroviruses (RCRs) (Delviks-Frankenberry et al., 2013). However, the
probability of generating a RCR identical to XMRV is extremely low
(Delviks-Frankenberry et al., 2013). PreXMRV-1 is a xenotropic retro-
virus defective for autonomous replication due to a 16-nt deletion in
gag and a þ1 frameshift mutation in pol (Paprotka et al., 2011;
Delviks-Frankenberry et al., 2013). PreXMRV-2 is a complete non-
ecotropic endogenous retrovirus that however failed to propagate into
the entire xenograft (Paprotka et al., 2011) and appeared non infec-
tious during in vitro infection assays (Delviks-Frankenberry et al.,
2013). In contrast, XMRV was constantly detected since its ﬁrst appe-
arance in late passage xenografts (Paprotka et al., 2011). This indicated
that XMRV had rapidly infected all human cells of the xenografts, and
showed that XMRV constitutes a new gamma retrovirus with
enhanced infectivity and tropism for human cells. Although XMRV is
not a human pathogen (Sturzel et al., 2013), it may warrant special
attention due to the frequent contamination of cell lines and biopsies
by xenotropic-related murine leukemia retroviruses (X-MLV) (Hempel
et al., 2013). It also provides the opportunity to study the ﬁtness of a
new retrovirus directly arising from genetic recombinations between
non-infectious precursors. It may also be useful to design XMRV-
derived vectors as tools for gene transfer, as recently exempliﬁed by
Cervantes-Garcia et al. (2011) who developed XMRV-derived vectors
with an internal cytomegalovirus promoter. Several studies identiﬁed
cellular restriction factors (e.g. APOBEC3, tetherin) (Groom et al., 2010;
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Chaipan et al., 2011) that inhibit XMRV multiplication in human cells.
However, less information is available concerning viral determinants
of its transcription and replication in human cells. Using the XMRV
promoter—luciferase reporter assays, studies have shown that andro-
gen (Dong and Silverman, 2010; Rodriguez and Goff, 2010) and tumor
necrosis factor alpha (TNFα) (Sakakibara et al., 2011) stimulate XMRV
transcription in human cells. However, most of these promoter
reporter gene-based studies were performed using plasmid constructs
and not integrated retroviruses. Moreover, several studies designed to
assess XMRV infectivity were carried out with a Murine Leukemia
Virus (MLV)-reporter genome trans-complemented with XMRV pro-
teins and such hybrid retroviral particles may exhibit differences in
virus-host interactions. Sturzel et al. (2013) constructed the ﬁrst
replication-competent XMRV reporter-viruses to monitor XMRV infec-
tivity in human cell lines and primary cells. However, the comparative
analysis of the biological properties of XMRV cis-sequences is facili-
tated by the use of single-round native (absence of superinfection)
and/or chimeric vectors whose expression is analyzed at early times
post-transduction. In this context, we have elaborated new genetic
tools enabling a single-round transduction of a gfp reporter gene
within an XMRV-based backbone that can be easily monitored by ﬂow
cytometry. Our analysis revealed that the set of XMRV vectors we
constructed did not allow efﬁcient gfp reporter gene expression in
human cells compared to MLV/MSCV- (Murine Stem Cell Virus) and
HIV-1- (type 1-Human Immunodeﬁciency Virus) based vectors. We
also show that the XMRV encapsidation signal was less efﬁcient than
the MSCV encapsidation signal. However, the study of replicative
XMRV indicated that the virus could efﬁciently propagate and accu-
mulate to a high copy number in human prostate cells. This was
shown to result from the low intrinsic expression of XMRV that allows
multiple superinfection events before infected cells become resistant
to superinfection through XMRV Env-mediated viral interference.
Results and discussion
Design of XMRV-based vectors
The XMRV-based vectors used here were derived from pCDNA3.1
(-)VP62 (NIH 11881) (Dong et al., 2007), a pCDNA3.1(-) plasmid
containing the complete cDNA of the genomic RNA from the XMRV
VP62 isolate under the control of the CMV promoter, PCMV, since U3
is absent from the 50 part of the viral genome (Fig. 1A). We ﬁrst
constructed a replication-defective XMRV-derived vector, pXV-PCMV,
carrying a deletion encompassing most of the gag, pol and env
genes, and marked it with an enhanced green ﬂuorescent protein
(eGFP) gene under the control of an internal ribosome entry site
(IRES) (Fig. 3A). Importantly, the deletion spares the region homo-
logous to the complete (or large) Ψ sequence of MSCV (Figs. 1B and
3A). pXV-LTR was then derived from pXV-PCMV by reconstituting a
complete 50LTR structure (Fig. 1B). It should be noted that the U5
sequence of the 30 LTR in the gfp-marked XMRV vectors was not
reconstituted: indeed, this sequence is dispensable for the genera-
tion of infectious retrovirus since the viral RNA normally terminates
at the 30 end of the 30R sequence that contains a polyadenylation
signal. This was a posteriori conﬁrmed by analyzing the transduction
efﬁciency of the encapsidated RNA encoded by the gfp-marked
XMRV vector. Furthermore, the 30U5 sequence that is required for
viral integration is naturally regenerated during the reverse tran-
scription process from the 50U5 sequence in the 50 LTR.
To examine the relationship between promoter sequences of
XMRV, its parental Pre-XMRV1 and PreXMRV-2 proviruses, other X-
MLV frequently detected in laboratory cell lines, endogenous and
exogenous retroviruses, we performed maximum likelihood phylo-
genetic analyses (Fig. S1). Depending on their LTR structure, the
xenotropic MLV-related proviruses could be divided into four
subgroups, termed X-I to X-IV (Tomonaga and Cofﬁn, 1999). Inter-
estingly, the PreXMRV-1 and XMRV U3 regions cluster with the X-I
subgroup, as well as X-MLV strains frequently isolated from cell
lines (N417, LaCP4, VCaP, NFS-Th1 strains). The type X-I proviruses
include the previously identiﬁed proviruses Bxv1, NFS, CWM, that
encode infectious xenotropic viruses. The X-I proviruses differ from
the others by the presence of only one copy of region 1 as well as
the enhancer-rich region 4 (Fig. S2) (Tomonaga and Cofﬁn, 1999).
This subgroup also diverges from the other subgroups by a number
of single-base differences, some of which affecting enhancer motifs
(Fig. S2) (Tomonaga and Cofﬁn, 1999). Otherwise, the Pre-XMRV-2
U3 region clusters with the X-II and X-III subgroups, and some other
X-MLV laboratory-isolated strains (EKVX, DG-75). Strikingly, all RCRs
generated from PreXPRV-1 and PreXMRV-2 (Delviks-Frankenberry
et al., 2013) contain the PreXMRV-1 sequence, suggesting that it
could be positively selected in vitro. This hypothesis is reinforced by
the observation that the X-MLVs infecting LAPC4 and VCaP were
replication competent, while the virus infecting EKVX had very low
infectivity (Sfanos et al., 2011).
To compare the expression of XMRV to a gammaretrovirus
efﬁciently expressed in human cells, the MigR1 MSCV-vector was
used, that is also a laboratory-generated variant, derived from PCC4-
cell-passaged myeloproliferative sarcoma virus (MPSV) (Pear et al.,
1998; Stocking et al., 1985). MigR1 is efﬁciently expressed in various
cells including human hematopoietic (Conneally et al., 1996), breast
(Bardy et al., 1997) and also prostate cancer (Whelan et al., 2009)
cells. MSCV-derived vectors such as MigR1 were further optimized
with an extended packaging region of the LN retroviral vectors for
high viral titer harboring a mutated MoMLV gag start codon and an
upstream region comprising Moloney Murine Sarcoma Virus (Mo
MSV) sequences, whose combinations abrogate the synthesis of
Glycogag (Hawley et al., 1994). Of note, XMRV also lacks the classical
gPr80Gag sequence (Nitta et al., 2012). The MSCV LTR differs from the
MoMLV LTR in the U3 region by the deletion of one of the 75-bp
repeats (as in XMRV U3) and eight point mutations (Fig. S2).
Comparative analyses of the VP62-XMRV, MSCV and MoMLV U3
promoters (Fig. S2) revealed that the XMRV promoter shares respec-
tively 64.4 and 72.0% identity and possesses 17.5 and 7.2% gaps with
the MoMLV and MSCV U3 regions. Therefore, the strong U3 promoter
of MSCV is more closely related to XMRV than to MoMLV. Thus we
chose the MigR1 vector as a comparative reference to measure XMRV
ﬁtness in human prostate cells.
Weak functional viral titers of the XMRV-derived vectors
compared to the MLV-derived vectors in LNCaP cells
Recombinant GFP-marked virus production was carried out by
transient co-transfection of HEK 293 T cells with the retroviral vector-
encoding plasmids and pHG1, encoding the XMRV proteins (Fig. 1A).
Functional viral titers, deﬁned as the number of transducing units
allowing GFP expression per unit of viral suspension volume, were
determined by transducing human prostate cancer LNCaP cells, since
previous studies reported that they express a functional androgen
receptor and support high levels of XMRV expression and replication
(Rodriguez and Goff, 2010). Transduction by serial dilutions of vector
stocks followed by cytoﬂuorometric quantiﬁcation of GFP-expressing
cells (GFPþ-cells) 2 days post-transduction were used to deﬁne the
linear phase of transduction (3–30% of GFPþ cells) and to calculate
the viral titer (transducing unit (TU)/mL) in the presence or absence
of dihydrotestosterone (DHT), that was previously described as
increasing XMRV but not MoMLV promoter activity (Dong and
Silverman, 2010; Rodriguez and Goff, 2010).
As previously reported for other MLV-based vectors (Dong et al.,
2008), transduction with the MigR1 vector trans-complemented
with XMRV proteins resulted in efﬁcient gfp transgene expression in
LNCaP cells, as compared to the MigR1 vector trans-complemented
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with the MLV Gag–Pol and VSV-G proteins (Fig. 1B). On the contrary,
transduction with the XV-LTR vector led to a very weak viral titer;
on average 54718 times (standard error of the mean (SEM), n¼5)
lower than for MigR1 (Fig. 1B). The absence of signiﬁcant pseudo-
transduction (the direct transduction of eGFP protein through its
binding to or encapsidation into viral particles (Nash and Lever,
2004) was veriﬁed in parallel experiments in which transduced cells
were treated at the time of transduction with an inhibitor of
reverse-transcriptase, AZT (see Fig. S3 for a representative cyto-
metric analysis). DHT treatment did not signiﬁcantly increase the
titers of the MigR1 and XMRV-derived vectors (Fig. 1B). Similar
results were also obtained with the DU145 prostate cell line (data
not shown). Overall, these data suggest that viral proteins encoded
by XMRV are fully functional, but that cis-regulatory sequences of
the XMRV genome present in the XV-LTR vector are not optimal for
production by HEK 293 T cells, transduction and/or expression in
LNCaP target cells.
Considering the weak functional viral titers of the XMRV
derived-vectors, LTR-driven transcription was then analyzed by
monitoring gene reporter expression in HEK 293 T-producing cells
(Fig. 2A) and in LNCaP target cells (Fig. 2B) transiently transfected
with the plasmids pMigR1 or pXV-LTR. The gfp transgene under the
control of the XMRV promoter led respectively to 571 times (SEM,
n¼10) and 2.070.2 times (SEM, n¼2) fewer GFPþ-cells among
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Fig. 1. XMRV-derived vectors exhibit low viral titers in LNCaP cells as compared to MLV-derived vectors. (A) Structure of the XMRV-VP62 isolate cloned into pCDNA3.1(-) (14)
and of the derived trans-complementing pHG1 plasmid used to express XMRV Gag–Pol–Env (GPEXMRV) (16). (B) Structure and viral titers of the MigR1 and XMRV-derived
vectors. Viral particles were produced upon transient transfection of HEK 293 T cells with the indicated vectors and the XMRV Gag–Pol–Env protein-encoding plasmid pHG1
(GPEXMRV) or plasmids encoding the MLV Gag–Pol and VSV-G proteins (GPMLVþEVSV-G). Non-ultracentrifuged supernatants (1 mL) were used to transduce LNCaP cells. GFP
expression in transduced cells was analyzed by ﬂow cytometry 2 days post-transduction, following or not a 24 h treatment with 100 nM DHT. Viral titers are numbers of
infected GFPþ- LNCaP cells per unit volume of viral supernatant. The results presented were obtained from at least 3 independent experiments, conducted with 2 different
plasmid preparations (mean7standard error of the mean (SEM), statistically analyzed by performing a two-tailed Student t test, nnnpo0.001). eGFP: enhanced green
ﬂuorescent protein; IRES: internal ribosome entry site; LTR: long terminal repeat; PCMV: cytomegalovirus immediate early promoter; pA: polyadenylation signal; Ψ:
packaging sequence; TU: transduction unit.
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Fig. 2. Comparison of the XMRV and MSCV promoter activity in transiently transfected human cells. Retroviral vector-encoding plasmids pMigR1 and pXV-LTR were used to
transiently transfect HEK 293 T cells (panel A) or LNCaP cells (panel B). Percentages of GFPþ-cells and mean ﬂuorescence intensity of GFPþ-cells were determined 2 days
later by ﬂow cytometry. The results presented are the average of 10 (panel A) and 4 (panel B) independent experiments, conducted with 3 different plasmid preparations
(mean7SEM, statistically analyzed by performing a two-tailed paired Student t test, npo0.05; nnpo0.005; nnnpo0.001).
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transfected HEK 293 T cells and LNCaP cells than the percentages
obtained when the gfp transgene was under the control of the MSCV
promoter. The mean ﬂuorescence intensity (MFI) of the XMRV
promoter-driven gfp transgene expression was also signiﬁcantly
weaker than the MFI of MSCV promoter-driven gfp transgene
expression, 1.370.2 times (SEM, n¼10) and 1.670.3 times (SEM,
n¼2) in HEK 293 T cells and LNCaP cells respectively. This indicates
that the activity of the XMRV promoter is intrinsically weaker than
that of the MSCV promoter, especially in HEK 293 T cells. This lower
expression in productive cells consistently correlates with the
weaker viral titer of the XMRV-derived vectors observed, as com-
pared to MSCV-derived vectors (Fig. 1B). Thus, we further explored
the impact of XMRV promoter and other cis-regulatory sequences on
encapsidation and proviral expression.
RNA packaging into XMRV retroviral particles
Assembly of retroviral particles normally entails the selective
encapsidation of viral genomic RNA due to recognition by Gag of a
cis-acting packaging signal termed “Ψ” in the viral RNA. The minimal
encapsidation signal, or core encapsidation signal (ΨCES), can be easily
identiﬁed thanks to the presence of characteristic stem-loop structures
that promote RNA dimerization and encapsidation (D'Souza and
Summers, 2004). A comparative analysis of these sequences between
natural exogenous retroviruses (MoMLV, MoMSV), endogenous retro-
viruses (PreXMRV-1, Pre-XMRV-2) and laboratory-selected variants
(PreXMRV-1/2 RCR, XMRV, MigR1) is presented in Fig. S4A. Interest-
ingly, in the stem loop C (SL-C), polymorphism is mainly observed in
positions that are not involved in base pair hybridization, or in
positions associated to other mutations allowing hybridization. This
suggests that the stem loop structure should be conserved in these
variants. Strikingly, ΨCES corresponds to a region of recombination
between PreXMRV-1 and Pre-XMRV-2 RNA, observed in 7 out of 10
RCRs (including XMRV; Fig. S4B). Of note, the XMRV packaging
sequence is identical to that of 3 out of the 9 RCRs previously
generated in vitro by Delviks-Frankenberry et al. (2013).
We explored the process of encapsidation into XMRV viral particles
produced in HEK 293 T cells upon transient co-transfection of pHG1
(Fig. 1A) encoding the XMRV Gag–Pol–Env proteins, and the XMRV-
derived vector-encoding plasmids pXV-PCMV and pXV-LTR, along with
the pMigR1 shuttle construct. Given that sequences additional to the
ΨCES core element are generally required for optimal encapsidation
(Hibbert et al., 2004), we also generated a chimeric construct, pXV-
PCMV-ΨMSCV, in which the extended Ψ region of XMRV (Fig. S4) was
replaced by the heterologous MigR1Ψ- extended region (Fig. 3A), and
a control vector lacking the XMRV Ψ sequence, pXV-PCMV-ΔΨ
(Fig. 3A). There was no signiﬁcant difference in the total amount of
RNA extracted from the viral particles contained in the same volume
of productive cell supernatant, whatever the retroviral vector tested
Fig. 3. Encapsidation efﬁciency in XMRV-derived particles. (A) Structure of the pXV-
PCMV, pXV-PCMV-ΔΨ and pXV-PCMV-ΨMSCV shuttle plasmids. See Fig. 1 for abbrevia-
tions. Numbers indicate nucleotide position in the corresponding wild type retroviruses,
position 1 corresponding to the ﬁrst nucleotide of the R region in the 50LTR. (B) Total
RNA content in viral particles. Viral particles were produced upon transient transfection
of HEK 293Tcells with the XMRV Gag–Pol–Env proteins encoding-plasmid pHG1 and
the indicated vectors. Total RNAs extracted from viral particles concentrated by
ultracentrifugation of 10 mL of supernatant were quantiﬁed by spectrophotometry.
Control was total RNA extracted from supernatants of productive cells non-transfected
or transfected without pHG1 plasmid. (C) gapdh mRNA content in viral particles.
Glyceraldehyde 3-phosphate dehydrogenase (gapdh) RNA content of viral particles was
determined for each vector by RT-qPCR and normalized by total RNA content of viral
particles. As a control, gapdh RNA content was determined by the same method in the
ultracentrifuged supernatant of productive cells non-transfected or transfected without
pHG1 plasmid. (D) Relative encapsidation efﬁciency of the gfp-marked retroviral vector
RNA. gfp RNA content of viral particles was determined by RT-qPCR and normalized by
both total RNA content of viral particles and the transcription level of the indicated
retroviral vector in productive cells, as described by the following formula: encapsida-
tion efﬁciency¼(gfp RNA content of viral particles/total RNA content of viral particles)/
(gfp mRNA content of productive cells/gapdh mRNA content of productive cells) x C;
where C is a constant factor chosen such as MigR1 encapsidation efﬁciency is 100%.
Differences in encapsidation efﬁciency within vectors containing the extended ΨMSCV
encapsidation sequence or within vectors containing the extended ΨXMRV encapsida-
tion sequence were not signiﬁcant. For all panels, the results presented correspond to at
least 2 independent experiments, conducted with 2 different shuttle plasmid prepara-
tions (mean7SEM, statistically analyzed by performing a two-tailed Student t test,
npo0.05, nnpo0.005, nnnpo0.001).
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(Fig. 3B), suggesting that as for MoMLV (Rulli et al., 2007), cellular
mRNA and viral XMRV RNA compete for encapsidation into retroviral
particles. This was conﬁrmed by our observation that gapdh mRNA
could be detected in all viral particles contained in productive cell
supernatants (RT-q-PCR quantiﬁcation, Fig. 3C). Overall, this indicates
that in all cases, the level of viral RNA produced in the cells was not
sufﬁcient to saturate the available RNA binding sites within the
retroviral particles being formed. These observations led us to deﬁne
encapsidation efﬁciency of the gfp-marked retroviral vectors as pre-
viously described by Rulli et al. (2007) (Fig. 3D). Brieﬂy, the amount of
gfp RNA detected in a viral supernatant was normalized by both the
total amount of RNA per volume unit of supernatant (which consti-
tutes a normalization of the relative amount of retroviral particles in
the supernatants tested, Fig. S5A) and the relative transcription level of
each vector in productive cells (RT-q-PCR quantiﬁcation, Fig. S5B). The
annotated XMRV Ψ sequence clearly corresponded to a functional
signal for encapsidation, as assessed by the poor encapsidation
efﬁciency of pXV-PCMV-ΔΨ (37713 times (SEM, n¼3)) lower than
for the pXV-PCMV parental construct (Fig. 3D). The trend towards a
higher concentration of gapdhmRNA in the supernatant of pXV-PCMV-
ΔΨ co-transfected cells agrees with competition for encapsidation
between cellular and viral RNA. We also observed that vectors
containing theΨMSCV encapsidation sequence were signiﬁcantly more
efﬁciently encapsidated than vectors with the ΨXMRV sequence (on
average 371 times (SEM, n¼4, 2 independent experiments))
(Fig. 3D). This was corroborated by a 2-fold difference between
encapsidation efﬁciency of MigR1 and XV-LTR transcripts despite
extensive sequence differences between these two vectors (Fig. 3D).
Taken together, these results suggest that the XMRV encapsidation
region is functional but less efﬁcient than the MSCV encapsidation
region. As mentioned above, theΨ sequence of XMRV originates from
the recombination of the corresponding 50 part of PreXMRV-1 and the
30 part of PreXMRV-2 (Paprotka et al., 2011). It is thus likely that such a
chimeric Ψ sequence is not optimal for RNA encapsidation. However,
the lower encapsidation efﬁciency of XMRV could not fully account for
the difference in the functional viral titers observed between the
MigR1 and XV-LTR vectors (Fig. 1). This implies that such a difference
might originate from other limiting steps in the retroviral cycle such as
viral expression in target cells.
XMRV U3 is weaker than the MSCV and HIV-1 U3 promoters
XMRV expression was then studied in a proviral context, to
take into account the potential effect of the integration environ-
ment. A comparative cytometric analysis of GFP expression at
3 and 10 days post-transduction was performed in cells trans-
duced with MigR1, XV-LTR, or the two newly generated chimeric
vectors MigR1-U3XMRV and XV-LTR-U3MSCV (Fig. 4A). We also
compared XMRV to two HIV-derived vectors, HIV-XCD3 (Tat-
proﬁcient) and HIV-XCD24 (that lacks all HIV proteins including
Tat), used as high level or basal models of HIV expression
respectively (Fig. 4B). To avoid biases in GFP expression measure-
ments between the different vectors caused by the cumulative
effect of their variable expression in productive cells and relative
encapsidation efﬁciency, quantitative-PCR was performed on
DNAs extracted from transduced cells to normalize our data by
the relative viral copy number, so as to compare expression levels
of each vector at an equal provirus number per cell. Transduction
experiments carried out in LNCaP (Fig. 4C and Fig. S6) showed that
transgene expression controlled by the XMRV promoter in XV-LTR
was 4.070.7 times (SEM, n¼2) weaker than transgene expression
controlled by the MSCV promoter in MigR1. The same results were
obtained with the chimeric constructs MigR1-U3XMRV and XV-LTR
respectively compared to the MigR1 and XV-LTR-U3MSCV con-
structs (2.570.2 fold and 771.6 fold (SEM, n¼2) differences in
total ﬂuorescence respectively), indicating that the U3 sequence is
the main element controlling transgene expression. As classically
performed to study the stability of transgene expression over time
(Manic et al., 2013; Pearson et al., 2008; Duverger et al., 2009), GFP
expression was analyzed on days 3 and 10 following transduction.
The vectors being non replicative, this experimental scheme
allows the analysis of transgene expression from total (uninte-
grated and integrated) viral DNA at early times, and only inte-
grated DNA at late time post-transduction. Stability of total ﬂuo-
rescence levels between days 3 and 10 for all vectors also indicated
that none of them underwent transcriptional extinction, as con-
ﬁrmed by the absence of any signiﬁcant effect of a reactivating
treatment with TSA performed on day 9. Other treatments such as
5-Aza dC alone or with DHT, TNFα or TSAwere also tested, without
any effect (data not shown). Moreover, these results indicate
that at early times post-transduction, transgene expression is
mainly expressed from XMRV-vector integrated DNA. Finally, the
comparison with HIV-1 vectors revealed that transgene expres-
sion controlled by U3XMRV (XV-LTR and MigR1-U3XMRV vectors)
was just slightly superior to transgene expression by HIV-
XCD24, a representative of an HIV-1 basal expression state, not
induced by Tat. In contrast, transgene expression by HIV-XCD3,
corresponding to a Tat-induced activated state of HIV expres-
sion, was on average 28710 times (SEM, n¼2) stronger than
transgene expression by U3XMRV-driven constructs. Cytometric
results were conﬁrmed by direct comparison of the gfp trans-
gene transcription level analyzed by RT-qPCR (Fig. 4D). Gfp
mRNA copies were 5.770.8 times (SEM, n¼2) less numerous
when transcribed from the XV-LTR vector than from the MigR1
or XV-LTR-U3MSCV vectors.
Overall, the cumulated effects of XMRV lower encaspidation
efﬁciency and lower expression in human cells could fully account
for the difference in the functional viral titers observed between
the MigR1 and XV-LTR vectors.
Low expression of XMRV in human cells delays interference
and allows viral copy accumulation
Finally, we investigated how the propagation of wild type XMRV
could be impacted by its relatively weak expression in prostate
cancer cells. Accordingly, we generated from pCDNA3.1(-)-VP62 a
wild type XMRV with reconstituted LTRs (pXMRV-LTR, Fig. 5A). Viral
particles were produced by transfection of HEK 293 T cells and used
to infect LNCaP cells. The evolution of provirus copy number was
followed by qPCR analysis of the cellular DNA of infected cells. In
these conditions, the number of wild type XMRV viral copies per
cell progressively increased with time to reach a plateau after two
weeks of culture at 4073 copies per cell (SEM, n¼3) (Fig. 5B). The
kinetics of wild type XMRV provirus accumulation suggested that
the low intrinsic level of individual provirus expression could allow
important accumulation of viral DNA copies by superinfection until
the establishment of viral interference. To assess this phenomenon,
gfp-marked MigR1 vectors used to superinfect native (non-infected)
or wild type XMRV-infected LNCaP cells 2, 4, 6 and 10 days after
primary infection (see experimental scheme Fig. 5C) at a multi-
plicity of infection (m.o.i.) of 0.4 (40% GFPþ-cells after MigR1
transduction in the absence of interference). MigR1 vectors were
trans-complemented with MLV Gag–Pol and XMRV Env (MigR1
GPMLV-EXMRV) or VSV-G (MigR1 GPMLVþEVSV-G) proteins, to reveal
XMRV envelop-dependent viral interference. Percentages of GFPþ-
cells were measured by ﬂow cytometry 2 days after superinfection
(Fig. 5D). LNCaP cells that were initially infected by wild type XMRV
progressively became refractory to superinfection by MigR1 pseu-
dotyped with XMRV Env protein, so that MigR1 transduction at m.o.
i. 0.4 became undetectable 10 days after XMRV infection. In contrast,
superinfection with MigR1 pseudotyped with VSV-G protein varied
less than 2 fold over time. Overall, these data show that a viral
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interference phenomenon mediated by the XMRV Env protein
began to signiﬁcantly limit superinfection events before the onset
of the plateau corresponding to the maximum number of provirus
copies.
We next examined if the kinetics and the maximum XMRV viral
copy accumulation were determined by the virus' level of expression.
To test this hypothesis, a chimeric XMRV (pXMRV-LTR-U3MSCV, Fig. 5A)
was constructed, in which the U3XMRV promoter was replaced by the
U3MSCV promoter, that is about 2.5 times stronger than U3XMRV in
LNCaP cells (cf. Figs. 4C and D). Viral particles were produced as
described for wild type XMRV, and used to infect LNCaP cells. The
number of chimeric XMRV provirus copies reached a plateau earlier
thanwild type XMRV, after only one week of culture, and its level was
on average 2272 copies per cell (SEM, n¼3) (Fig. 5B). In agreement
with our model, the wild type XMRV that harbors a weaker promoter
than chimeric XMRV leads to the accumulation of a higher provirus
copy number. The interference phenomenon was next investigated
using the same assay as described above for wild type XMRV. A faster
kinetics was observed for viral interference, as superinfection became
barely detectable on day 6 after the initial infection with chimeric
XMRV (Fig. 5D). On the other hand, superinfection with MigR1
pseudotyped with VSV-G protein showed no difference between wild
type and chimeric XMRV-infected cells. Finally, plotting the level of
interference versus the number of provirus copies clearly shows that
viral interference depends both on the provirus copy number and the
strength of the retrovirus promoter (Fig. 5E). Of note, we observed that
the copy number of wild type XMRV increased to reach a plateau at
about 40 copies per cell (Fig. 5B), whereas superinfection with MigR1
pseudotyped with XMRV Env protein became undetectable when the
XMRV copy number reached about half this value (Fig. 5E). Two
explanations could account for this apparent paradox. First, the
percentage of infected cells depends on the viral titer for a given cell
sensitivity to infection. Our viral interference assay used a relatively
weak titer of MigR1 virus (m.o.i. of 0.4; Fig. 5D), whereas the wild type
XMRV titer in the supernatant of the cell culture is very likely to
become far higher when every cell is infected with several copies of
XMRV. Moreover, new XMRV viruses are continuously produced in
the cell supernatant, unlike the one-time addition of exogenous
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MigR1. Furthermore, the sensitivity of our viral interference assay is
limited by background ﬂuorescence noise that precludes detection of
less than 0.5% ﬂuorescent cells, implying that a signiﬁcant but
relatively low infection rate is undetectable.
Such regulation of the number of accumulated viral DNA copies
by the onset of viral interference could account for our previous
observation that a maximal number of 40 copies per cell was
systematically reached in all our experiments. It may also explain
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why the prostate carcinoma cell lines 22Rv1 and CWR-R1, chroni-
cally infected with XMRV, carry 20 to 30 copies of integrated virus
(Paprotka et al., 2011; Knouf et al., 2009), numbers that are of the
same order of magnitude as those observed here in LNCaP cells.
Indeed, in this model, the maximum number of viral copies per
cell depends only on the expression level of the viral Env protein,
which itself depends only on the average number of proviral
copies and on the cell type, but not on the kinetics of the viral
infection.
Viral DNA accumulation is a hallmark of cytopathic effect (CPE)
caused by various retroviruses such as avian spleen necrosis virus
(Keshet and Temin, 1979), avian leukosis virus (ALV) (Weller et al.,
1980; Rainey and Cofﬁn, 2006), feline leukemia virus (Mullins et al.,
1986), HIV-1 (Pauza et al., 1990), mink cell focus-forming MLV
(generated from Xmv43/Bxv1endogenous MLV in certain mice
(Hoggan et al., 1986; Yoshimura et al., 2001), and Friend-MLV (Jung
et al., 2004). CPE and sensitivity to viral DNA accumulation may vary
depending on virus and cell determinants. Actually, during chronic
infection experiments performed in LNCaP cells, XMRV DNA accu-
mulation was not associated to a dramatic CPE, a characteristic
compatible with its maintenance at high levels in CWR22 and 22Rv1
cell lines (Paprotka et al., 2011; Knouf et al., 2009), and its horizontal
spread to the non-xenograft human colorectal carcinoma RKO cell
line (Zhang et al., 2011). Similarly, XMRV infection of various cell lines
has not been associated to CPE (Sturzel et al., 2013), except in Raji B
cells, that were more efﬁciently infected by XMRV than LNCaP cells
(þ35% infectivity) and presented multinucleated syncitia forma-
tion in the week following XMRV infection (Sturzel et al., 2013).
The hypothesis that viral DNA accumulation was due to the
absence of superinfection interference was early suggested (Temin,
1988). Indeed, HIV-1 DNA accumulation has been clearly correlated
with multiple infection events in the CD4þ C8166 T cell line, which
accumulates up to 80 copies of viral DNA per cell, against only
4 copies in the presence of neutralizing antibodies to prevent
superinfection (Pauza et al., 1990). Accordingly, envelope mutations
have been associated with modiﬁed tropism and viral DNA accumu-
lation in Friend-MLV (Jung et al., 2004). Moreover, Rainey and Cofﬁn
have shown that the host-range of ALV mutants exhibiting dimin-
ished resistance to superinfection cause a buildup of viral DNA forms
(Rainey and Cofﬁn, 2006). Our study reveals that the strength of the
retroviral promoter is part of these virus-host cell adaptation
determinants that establish a link between DNA accumulation and
viral envelope interference.
Conclusions
We have characterized basic biological properties of XMRV, a
direct product of a genetic recombination event between two
endogenous murine retroviruses, that crossed barrier species to be
propagated into human prostate cancer cells xenografted into mice.
XMRV retroviral proteins seem to be fully functional in human cells,
as compared to MLV proteins. The lower functional viral titer
observed for the XMRV recombinant vectors, as compared to a
classical murine retroviral vector, originates in the cis-regulatory
sequences regulating viral RNA encapsidation into viral particles and
provirus expression in infected human cells. Indeed, our results
indicate that the recombinant Ψ sequence of XMRV (originating
from the recombination of the corresponding 50 part of PreXMRV1
and the 30 part of PreXMRV2 (Paprotka et al., 2011)) is not optimal for
encapsidation. The apparent high sensitivity of cis-regulatory nucleic
acid sequences to the crossing of barrier species and to genetic
recombination may reﬂect higher constraints on sequences that
interact with viral or host factors. In this respect, the present study
shows that XMRV exhibits a low level of expression in human cells,
similar to the expression level of a Tat-defective HIV-1 provirus.
Unexpectedly, the low level of XMRV expression allows multiple
infection events to occur before viral interference is established. As a
consequence, the viral copy number per cell increases up to 40
copies, and this has to be compared to the maximum number of MLV
proviruses in infected murine NIH3T3 cells, which is around 10
copies (Odawara et al., 1998), and to the maximum number of HIV
proviruses in infected human lymphocytes, on average 1 copy in
patients' cells, and classically 1 to 4 copies in cells infected in vitro
(Josefsson et al., 2013). The impact of the accumulation of a high viral
copy number on virus and host biology is an interesting issue.
in vitro, the correlation between low expression and high copy
accumulation characterized in this study for XMRV may explain the
efﬁcient spreading of the virus as contaminant, a situation that could
also concern other recombinant retroviruses currently detected in
many laboratory cell lines.
Materials and methods
Plasmid and vector cloning
The genetic organization of lentiviral and gamma retroviral
vectors is presented in Table S1, Figs. 1 and 3–5. Vectors derived
from MigR1 (Pear et al., 1998) were named MigR1-X, X being their
main modiﬁcation compared to the parental vector. Similarly, vectors
derived from the pCDNA3.1(-)VP62 reference plasmid, containing the
full XMRV genome (Dong et al., 2007), were named XMRV-X. XMRV
vectors derived from the pCDNA3.1(-)VP62 construct in which the
XMRV protein-encoding genes were replaced by an IRES-gfp cassette
were named pXV-X. Finally, the names of lentiviral vectors present
the HIV- preﬁx. For all constructs, an additional “p” was used for the
plasmid form of the vectors. All the plasmids generated for this study
were veriﬁed by digestion and sequencing at least of the modiﬁed
junctions. All primers used for vector cloning and sequencing are
described in Table S2.
pHIV-XCD3 is a plasmid encoding an HIV NL4.3 Δenv gfpþ vector,
derived from pNL4.3 (Manic et al., 2013). pHIV-XCD24 is a plasmid
encoding an LTRHIV-gfp retroviral genome but no HIV proteins (Manic
et al., 2013). To construct a gfp-encoding XMRV, pCDNA3.1(-)VP62
(Dong et al., 2007), was ﬁrst mutagenised to introduce the PmlI and
AsiSI restriction sites just downstream of the stop codon of the Env
ORF, using the QuikChange XL Site-Directed Mutagenesis Kit (Agilent
Technologies Inc., Santa Clara, CA) and the OBM273/OBM274 primers.
The IRES-gfp fragment excised from pMigR1 (Pear et al., 1998) upon
digestion with HpaI and PacI was then introduced into pCDNA3.1(-)
VP62 opened by PmlI and AsiSI. pXV-PCMV was derived from this
construct by deletion of the gag, pol and Env ORFs obtained upon PCR
ampliﬁcation using the OBM261/OBM277 primers and self-ligation of
the resulting amplicon, followed by removal of the BGH (Bovine
Growth Hormone) polyadenylation sequence by BstBI/AﬂII digestion,
blunting treatment and self-ligation. pXV-PCMV-ΨMSCV was con-
structed by replacing the XMRV large Ψ region of pXV-PCMV by the
corresponding region of pMigR1. A unique AsiSI restriction site was
inserted just upstream of theΨ sequence of both plasmids upon PCR
mutagenesis using the OBM319/OBM320 primers for pMigR1, and the
OBM321/OBM322 primers for pXV-PCMV. The Ψ region was then
excised from the mutagenised pMigR1 by AsiSI/HpaI digestion and
inserted between the AsiSI and AfeI restriction sites of themutagenised
pXV-PCMV. pXV-PCMV-ΔΨ was also obtained from the mutagenised
pXV-PCMV by an AsiSI/AfeI digestion, blunting treatment and self-
ligation. To construct pMigR1-U3XMRV, the 50 part of pMigR1 was ﬁrst
deleted by NdeI/XhoI digestion, blunting treatment and self-ligation.
The AscI/BmgBI fragment excised from pXV-PCMV was then inserted
into this intermediate construct opened with the same enzymes, to
replace the corresponding gfp-30U3 fragment. The 50 part of pMigR1
was then reconstituted upon insertion of the SapI/BmgBI fragment
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excised from pMigR1 into the corresponding sites of this last inter-
mediate. To reconstitute a complete 30 LTR in pCDNA3.1(-)-VP62, the
U3-R region and the R-U5-PSI region of this plasmid were ﬁrst
ampliﬁed using the OBM335/OBM336 and OBM337/OBM338 pri-
mers respectively. A fusion PCR was then performed with the
OBM335/OBM338 primers on the previously obtained amplicons,
resulting in the ampliﬁcation of a reconstituted XMRV LTR-
containing fragment, which was cloned using the pGem-T-easy kit
(Promega, Madison, WI, US) following the manufacturer's instruc-
tions (pGem-T-easy-LTRXMRV). The complete LTR was ﬁnally ampli-
ﬁed using the OBM380/OBM392 primers and introduced into the
AscI/KasI-opened pCDNA3.1(-)VP62 using the In-Fusion HD EcoDry
Kit (Clontech, Mountain View, Ca, US) following the manufacturer's
instructions. The 50 LTR was similarly reconstituted, by ampliﬁcation
of the LTR-containing fragment from pGem-T-easy-LTRXMRV using
the OMB393/OBM394 primers and fusion to the 30 LTR-reconstituted
intermediate opened with MluI and SacII, using the In-Fusion HD
EcoDry Kit (Clontech). This kit was also used to obtain a construct
with the complete 50LTR and a chimeric 30 end composed of U3MSCV
and RXMRV. This was achieved by serial PCR performed on pXV-LTR-
U3MSCV using OBM430/OBM431, OBM431/OBM432 and OBM433/
OBM434, that result in an amplicon containing U3MSCV ﬂanked by
XMRV sequences and the PmlI and SfoI restriction sites. This amp-
licon was then fused to the pXMRV-LTR opened with PmlI and SfoI.
pXMRV-LTR-U3MSCV was ﬁnally constructed from this intermediate,
with complete 50 and 30 LTRs and a chimeric U3MSCV promoter, upon
digestion with AscI and ligation with the corresponding fragment
from pXMRV-LTR, obtained with the same enzyme. pXV-LTR-U3MSCV
was obtained from a previously constructed intermediate by repla-
cing the U3 region of pXV-PCMV by the corresponding sequence of
pMigR1 upon insertion of the BmgBI/AscI fragment excised from
pMigR1 into pXV-PCMV opened with the same enzymes. Finally, to
construct pXV-LTR with a complete reconstituted 50LTR, the PvuI
fragment was excised from the pXMRV-LTR containing the complete
50LTR and ligated it to the pXV-PCMV fragment obtained by PvuI
digestion that removed the complete CMV promoter and the R-U5
sequence.
Cell lines and culture conditions
HEK 293 T cells (CRL-11268, ATCC) and LNCaP cells (CRL-1740,
ATCC) were respectively cultured in Dulbecco's Modiﬁed Essential
Medium (DMEM) and RPMI-1640, both supplemented with 10% fetal
bovine serum, 100 U/mL penicillin and 0.1 mg/mL streptomycin at
37 1C, in 5% CO2. All media and supplements for cell culture were
purchased from Gibco-Invitrogen (Carlsbad, CA, US). All cell lines were
mycoplasma-free.
Virus production
Viruses were produced upon calcium-phosphate transfection of
HEK 293 T cells plated at 1105 cells/well in 6-well plates (BD Falcon,
BD Biosciences, Oxford, UK) 3 days earlier. Proportionality was applied
for bigger surfaces. The culture medium was changed 2 h before
transfection. Gamma retroviral vectors trans-complemented with
XMRV proteins were produced by co-transfection with 2.5 μg of a
2:1 mix of retroviral vector and the Gag–Pol–Env encoding plasmid
pHG1 kindly provided by Kate Bishop (Groom et al., 2010). Gamma
retroviral vectors trans-complemented with the MLV Gag–Pol proteins
and VSV-G (Vesicular Stomatitis Virus Envelope Glycoprotein) were
produced by co-transfection with 2.5 μg of a 8:3:1 mix of retroviral
vector, pVpack-GP (Stratagene, La Jolla, CA, US) and pMD.G (Ory et al.,
1996). Lentiviral vectors trans-complemented with HIV Gag–Pol and/
or VSV-G were produced as previously described (Manic et al., 2012).
Wild type XMRVwas produced by transfectionwith 2.5 μg of pXMRV-
VP62-LTR or pXMRV-VP62-LTR-U3MSCV. The mediumwas changed 8 h
after transfection, after washing with Dulbecco's phosphate-buffered
saline (DPBS, Gibco-Invitrogen, Carlsbad, CA, US). Supernatants were
harvested on days 3 and 4 post-transfection, centrifuged ﬁrst at 570 g
for 5 min, then at 1370 g for 20 min at 4 1C, and stored at 80 1C.
Percentage and mean ﬂuorescence intensity (MFI) of GFP-positive
productive cells were estimated by cytometry on day 4 post-transfec-
tion, with a FACSCalibur (BD Biosciences).
Transduction experiments
LNCaP cells were plated 3 days before infection at 1.6105 cells/
well in 12-well plates (BD Falcon, BD Biosciences, Oxford, UK), so that
they reached 3105 cells/well on the day of infection. Cells were
infected with 1 mL of pure supernatant for defective retroviruses, or
with 100 μL of supernatant diluted in RPMI for replicative XMRV. The
percentage and MFI of GFP-positive infected cells were estimated by
cytometry at 2, 3 and/or 10 days after infection, with a FACSCalibur.
When used, 30-azido-30-deoxythymidine (AZT, 25 μM, Sigma-Aldrich,
St. Louis, MO, US) was added to the cell medium at the time of
transduction. When used, dihydrotestosterone (DHT, 100 nM, Sigma-
Aldrich), trichostatine A (TSA, 200 nM, Sigma-Aldrich), tumor-
necrosis factor α (TNFα, 10 ng/mL, BD Biosciences) and 20-deoxy-5-
azacytidine (5-Aza dC, 5 μM, Sigma-Aldrich) were added to the cell
medium one day before cytometric analysis.
Transfection
Transient transfections of HEK 293 T cells seeded in 6-well
plates at 8105 cells/well the previous day were performed by the
calcium-phosphate co-precipitation method with 2.5 μg of retro-
viral vector-encoding plasmids. Transient transfections of LNCaP
cells seeded in 12-well plates at 5105 cells/well the previous day
were performed using the Lipofectamine 2000 reagent (Invitro-
gen, Carlsbad, CA, US), according to the manufacturer's instruc-
tions, with 0.5 μg of retroviral vector-encoding plasmids.
Nucleic acid extraction and processing
For cellular DNA extraction, cells (3 to 6105 cells) from
trypsinized cultures were pelleted, washed once with PBS (Gibco-
Invitrogen) and stored at 80 1C. Cellular DNAwas isolated with the
QIAamp DNA Blood Mini Kit (Qiagen, Valencia, CA, US) and quanti-
ﬁed with a Nanovue spectrophotometer (GE HealthCare, Chalfont St.
Giles, UK). For RNA extraction from viral particles, supernatants were
ﬁrst concentrated 300 times by ultracentrifugation at 100,000g for
2 h at 4 1C and stored at 80 1C. RNAs were isolated using the
QIAamp Viral RNA Mini Kit (Qiagen) from 30 mL of concentrated
supernatants pre-treated for 30 min with 3 U of Turbo DNase
(Ambion, Austin, TX, US).
For cellular RNA extraction, cells (3105 to 1106 cells) from
trypsinized cultures were pelleted, washed once with PBS and stored
at 80 1C. Total cellular RNAs were isolated with the RNeasy Mini Kit
(Qiagen). gDNA (genomic DNA) contamination was removed upon
treatment with RNase-free DNAse (Roche Diagnostics, Indianapolis,
IN, US) according to manufacturer's instructions. Total cellular RNAs
were puriﬁed once more with the RNeasy Mini Kit, and quantiﬁed
with a Nanovue spectrophotometer.
For cDNA synthesis, RNAs extracted from viral particles (500 to
800 ng) and cellular RNAs (50 to 150 ng) were reverse-transcribed
with PrimeScriptTM Reverse Transcriptase (Takara Bio Inc., Shiga,
Japan) according to manufacturer's instructions, with speciﬁc
primers of the 30end of the genes or regions of interest (gapdh,
gfp, psi), using OBM242, eGFP-rev and PSI-A primers (Table S3).
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Quantitative PCR experiments
Ampliﬁcations were carried out on 2 μL (approximately 20 ng) of
gDNA or cDNA, in a ﬁnal volume of 10 μL, using the LightCycler
FastStart DNA Master HybProbe, LightCycler TaqMan Master or
LightCycler DNA Master SYBR Green I kits according to the manu-
facturer's instructions (Roche Diagnostics, Basel, Switzerland). Copy
numbers of targets were determined using 102 to 106 copies of
linearized target sequence-containing plasmids as a standard, as
recommended by Hou et al. (2010). All the targets, primers, probes
and conditions that were used are described in Table S3. Ampliﬁca-
tions were normalized by β-globin gene ampliﬁcation for cellular
DNA targets, and gapdh gene ampliﬁcation for RT-qPCR experiments.
Phylogenetic analyses
Multiple alignment, curation and maximum likelihood phylo-
geny, using MUSCLE (Edgar, 2004), Gblocks (Castresana, 2000),
PhyML (Anisimova and Gascuel, 2006), Dendroscope 3 (Huson and
Scornavacca, 2012), were employed for the different steps and
conﬁrmations of phylogenetic reconstructions (Dereeper et al.,
2008). U3 sequences of endogenous viruses present in C57BL/6J
mouse genome are listed in the supplementary information of Jern
et al. study (Jern et al. 2007).
Statistical procedures
Unless otherwise speciﬁed, experiments were independently
repeated at least twice. Data were analyzed with Microsoft Excel
(Microsoft Co., Redmond, US) and statistical signiﬁcance was
assessed by means of the two-tailed Student t tests. Asterisks
depict statistical signiﬁcance (npo0.05, nnpo0.005, nnnpo0.001).
Authors' contributions
Conceived and designed the experiments: FL, TT, SBM. Per-
formed the experiments: FL, SBM. Analyzed the data: FL, TT, SBM.
Contributed reagents/materials/analysis tools: MB. Wrote the
paper: FL, TT, SBM, MB, UH.
Acknowledgments
We thank Hervé Leh, Frédéric Subra, Sylvain Thierry and Olivier
Delelis for technical support and stimulating discussions. We espe-
cially thank Dr. Olivier Lespinet for his help on bio-informatics
analyses, and Anne Lise Haenni for her attentive reading. We also
thank two anonymous reviewers for their constructive suggestions
and comments. We also thank the NIH AIDS Reagent program that
provided the construct containing the XMRV genome.
FL holds a fellowship from the Ecole Normale Supérieure of
Cachan.
Appendix A. Supporting information
Supplementary data associated with this article can be found in
the online version at http://dx.doi.org/10.1016/j.virol.2014.03.006.
References
Achong, B.G., Trumper, P.A., Giovanella, B.C., 1976. C-type virus particles in human
tumours transplanted into nude mice. Br. J. Cancer 34, 203–206.
Anisimova, M., Gascuel, O., 2006. Approximate likelihood-ratio test for branches: a
fast, accurate, and powerful alternative. Syst. Biol. 55, 539–552.
Bardy, P., Conneally, E., Emerman, J.T., Lansdorp, P.M., Goss, G., Humphries, R.K.,
Eaves, C.J., 1997. Isolation and analysis of different subpopulations of normal
human breast epithelial cells after their infection with a retroviral vector
encoding a cell surface marker. Breast Cancer Res. Treat. 44, 153–165.
Castresana, J., 2000. Selection of conserved blocks from multiple alignments for
their use in phylogenetic analysis. Mol. Biol. Evol. 17, 540–552.
Cervantes-Garcia, D., Rojas-Martinez, A., Camerini, D., 2011. An XMRV derived
retroviral vector as a tool for gene transfer. Virol. J. 8, 284.
Chaipan, C., Dilley, K.A., Paprotka, T., Delviks-Frankenberry, K.A., Venkatachari, N.J.,
Hu, W.S., Pathak, V.K., 2011. Severe restriction of xenotropic murine leukemia
virus-related virus replication and spread in cultured human peripheral blood
mononuclear cells. J. Virol. 85, 4888–4897.
Conneally, E., Bardy, P., Eaves, C.J., Thomas, T., Chappel, S., Shpall, E.J., Humphries, R.
K., 1996. Rapid and efﬁcient selection of human hematopoietic cells expressing
murine heat-stable antigen as an indicator of retroviral-mediated gene transfer.
Blood 87, 456–464.
D'Souza, V., Summers, M.F., 2004. Structural basis for packaging the dimeric
genome of Moloney murine leukaemia virus. Nature 431, 586–590.
Delviks-Frankenberry, K., Paprotka, T., Cingoz, O., Wildt, S., Hu, W.S., Cofﬁn, J.M.,
Pathak, V.K., 2013. Generation of multiple replication-competent retroviruses
through recombination between PreXMRV-1 and PreXMRV-2. J. Virol. 87,
11525–11537.
Dereeper, A., Guignon, V., Blanc, G., Audic, S., Buffet, S., Chevenet, F., Dufayard, J.F.,
Guindon, S., Lefort, V., Lescot, M., Claverie, J.M., Gascuel, O., 2008. Phylogeny.fr:
robust phylogenetic analysis for the non-specialist. Nucleic Acids Res. 36,
W465–469.
Dong, B., Silverman, R.H., 2010. Androgen stimulates transcription and replication
of xenotropic murine leukemia virus-related virus. J. Virol. 84, 1648–1651.
Dong, B., Kim, S., Hong, S., Das Gupta, J., Malathi, K., Klein, E.A., Ganem, D., Derisi, J.
L., Chow, S.A., Silverman, R.H., 2007. An infectious retrovirus susceptible to an
IFN antiviral pathway from human prostate tumors. Proc. Nat. Acad. Sci. U.S.A.
104, 1655–1660.
Dong, B., Silverman, R.H., Kandel, E.S., 2008. A natural human retrovirus efﬁciently
complements vectors based on murine leukemia virus. PLoS One 3, e3144.
Duverger, A., Jones, J., May, J., Bibollet-Ruche, F., Wagner, F.A., Cron, R.Q., Kutsch, O.,
2009. Determinants of the establishment of human immunodeﬁciency virus
type 1 latency. J. Virol. 83, 3078–3093.
Edgar, R.C., 2004. MUSCLE: multiple sequence alignment with high accuracy and
high throughput. Nucleic Acids Res. 32, 1792–1797.
Groom, H.C., Yap, M.W., Galao, R.P., Neil, S.J., Bishop, K.N., 2010. Susceptibility of
xenotropic murine leukemia virus-related virus (XMRV) to retroviral restriction
factors. Proc. Nat. Acad. Sci. U.S.A. 107, 5166–5171.
Hawley, R.G., Lieu, F.H., Fong, A.Z., Hawley, T.S., 1994. Versatile retroviral vectors for
potential use in gene therapy. Gene Ther. 1, 136–138.
Hempel, H.A., Burns, K.H., De Marzo, A.M., Sfanos, K.S., 2013. Infection of
xenotransplanted human cell lines by murine retroviruses: a lesson brought
back to light by XMRV. Front. Oncol. 3, 156.
Hibbert, C.S., Mirro, J., Rein, A., 2004. mRNA molecules containing murine leukemia
virus packaging signals are encapsidated as dimers. J. Virol. 78, 10927–10938.
Hoggan, M.D., O'Neill, R.R., Kozak, C.A., 1986. Nonecotropic murine leukemia
viruses in BALB/c and NFS/N mice: characterization of the BALB/c Bxv-1
provirus and the single NFS endogenous xenotrope. J. Virol. 60, 980–986.
Hou, Y., Zhang, H., Miranda, L., Lin, S., 2010. Serious overestimation in quantitative
PCR by circular (supercoiled) plasmid standard: microalgal pcna as the model
gene. PLoS One 5, e9545.
Huson, D.H., Scornavacca, C., 2012. Dendroscope 3: an interactive tool for rooted
phylogenetic trees and networks. Syst. Biol. 61, 1061–1067.
Jern, P., Stoye, J.P., Cofﬁn, J.M., 2007. Role of APOBEC3 in genetic diversity among
endogenous murine leukemia viruses. PLoS Genet. 3, 2014–2022.
Josefsson, L., Palmer, S., Faria, N.R., Lemey, P., Casazza, J., Ambrozak, D., Kearney, M.,
Shao, W., Kottilil, S., Sneller, M., Mellors, J., Cofﬁn, J.M., Maldarelli, F., 2013.
Single cell analysis of lymph node tissue from HIV-1 infected patients reveals
that the majority of CD4þ T-cells contain one HIV-1 DNA molecule. PLoS
Pathog. 9, e1003432.
Jung, Y.T., Wu, T., Kozak, C.A., 2004. Novel host range and cytopathic variant of
ecotropic Friend murine leukemia virus. J. Virol. 78, 12189–12197.
Keshet, E., Temin, H.M., 1979. Cell killing by spleen necrosis virus is correlated with
a transient accumulation of spleen necrosis virus DNA. J. Virol. 31, 376–388.
Knouf, E.C., Metzger, M.J., Mitchell, P.S., Arroyo, J.D., Chevillet, J.R., Tewari, M., Miller,
A.D., 2009. Multiple integrated copies and high-level production of the human
retrovirus XMRV (Xenotropic Murine Leukemia Virus-Related Virus) from
22Rv1 Prostate Carcinoma Cells. J. Virol. 83, 7353–7356.
Manic, G., Maurin-Marlin, A., Galluzzi, L., Subra, F., Mouscadet, J.F., Bury-Mone, S.,
2012. 30 self-inactivating long terminal repeat inserts for the modulation of
transgene expression from lentiviral vectors. Hum. Gene Ther. Methods 23,
84–97.
Manic, G., Maurin-Marlin, A., Laurent, F., Vitale, I., Thierry, S., Delelis, O., Dessen, P.,
Vincendeau, M., Leib-Mosch, C., Hazan, U., Mouscadet, J.F., Bury-Mone, S., 2013.
Impact of the Ku complex on HIV-1 expression and latency. PLoS One 8, e69691.
McAllister, R.M., Nicolson, M., Gardner, M.B., Rongey, R.W., Rasheed, S., Sarma, P.S.,
Huebner, R.J., Hatanaka, M., Oroszlan, S., Gilden, R.V., Kabigting, A., Vernon, L.,
1972. C-type virus released from cultured human rhabdomyosarcoma cells. Nat.
New Biol. 235, 3–6.
Mullins, J.I., Chen, C.S., Hoover, E.A., 1986. Disease-speciﬁc and tissue-speciﬁc
production of unintegrated feline leukaemia virus variant DNA in feline AIDS.
Nature 319, 333–336.
F. Laurent et al. / Virology 456-457 (2014) 28–38 37
Nash, K.L., Lever, A.M., 2004. Green ﬂuorescent protein: green cells do not always
indicate gene expression. Gene Ther. 11, 882–883.
Nitta, T., Lee, S., Ha, D., Arias, M., Kozak, C.A., Fan, H., 2012. Moloney murine
leukemia virus glyco-gag facilitates xenotropic murine leukemia virus-related
virus replication through human APOBEC3-independent mechanisms. Retro-
virology 9, 58.
Odawara, T., Oshima, M., Doi, K., Iwamoto, A., Yoshikura, H., 1998. Threshold
number of provirus copies required per cell for efﬁcient virus production and
interference in moloney murine leukemia virus-infected NIH 3T3 cells. J. Virol.
72, 5414–5424.
Ory, D.S., Neugeboren, B.A., Mulligan, R.C., 1996. A stable human-derived packaging
cell line for production of high titer retrovirus/vesicular stomatitis virus G
pseudotypes. Proc. Nat. Acad. Sci. U.S.A. 93, 11400–11406.
Paprotka, T., Delviks-Frankenberry, K.A., Cingoz, O., Martinez, A., Kung, H.J., Tepper,
C.G., Hu, W.S., Fivash Jr, M.J., Cofﬁn, J.M., Pathak, V.K., 2011. Recombinant origin
of the retrovirus XMRV. Science (New York, N.Y.) 333, 97–101.
Pauza, C.D., Galindo, J.E., Richman, D.D., 1990. Reinfection results in accumulation of
unintegrated viral DNA in cytopathic and persistent human immunodeﬁciency
virus type 1 infection of CEM cells. J. Exp. Med. 172, 1035–1042.
Pear, W.S., Miller, J.P., Xu, L., Pui, J.C., Soffer, B., Quackenbush, R.C., Pendergast, A.M.,
Bronson, R., Aster, J.C., Scott, M.L., Baltimore, D., 1998. Efﬁcient and rapid
induction of a chronic myelogenous leukemia-like myeloproliferative disease in
mice receiving P210 bcr/abl-transduced bone marrow. Blood 92, 3780–3792.
Pearson, R., Kim, Y.K., Hokello, J., Lassen, K., Friedman, J., Tyagi, M., Karn, J., 2008.
Epigenetic silencing of human immunodeﬁciency virus (HIV) transcription by
formation of restrictive chromatin structures at the viral long terminal repeat
drives the progressive entry of HIV into latency. J. Virol. 82, 12291–12303.
Rainey, G.J., Cofﬁn, J.M., 2006. Evolution of broad host range in retroviruses leads to
cell death mediated by highly cytopathic variants. J. Virol. 80, 562–570.
Rodriguez, J.J., Goff, S.P., 2010. Xenotropic murine leukemia virus-related virus
establishes an efﬁcient spreading infection and exhibits enhanced transcrip-
tional activity in prostate carcinoma cells. J. Virol. 84, 2556–2562.
Rulli Jr, S.J., Hibbert, C.S., Mirro, J., Pederson, T., Biswal, S., Rein, A., 2007. Selective
and nonselective packaging of cellular RNAs in retrovirus particles. J. Virol. 81,
6623–6631.
Sakakibara, S., Sakakibara, K., Tosato, G., 2011. NF-kappaB activation stimulates
transcription and replication of retrovirus XMRV in human B-lineage and
prostate carcinoma cells. J. Virol. 85, 3179–3186.
Sfanos, K.S., Aloia, A.L., Hicks, J.L., Esopi, D.M., Steranka, J.P., Shao, W., Sanchez-Martinez,
S., Yegnasubramanian, S., Burns, K.H., Rein, A., De Marzo, A.M., 2011. Identiﬁcation of
replication competent murine gammaretroviruses in commonly used prostate
cancer cell lines. PLoS One 6, e20874.
Stocking, C., Kollek, R., Bergholz, U., Ostertag, W., 1985. Long terminal repeat
sequences impart hematopoietic transformation properties to the myeloproli-
ferative sarcoma virus. Proc. Nat. Acad. Sci. U.S.A. 82, 5746–5750.
Sturzel, C.M., Palesch, D., Khalid, M., Wissing, S., Fischer, N., Munch, J., 2013.
Utilization of replication-competent XMRV reporter-viruses reveals severe viral
restriction in primary human cells. PLoS One 8, e74427.
Suzuki, T., Yanagihara, K., Yoshida, K., Seido, T., Kuga, N., 1977. Infectious Murine
Type-C Viruses Released from Human Cancer Cells Transplated into Nude Mice.
Gann¼Gan 68, 99–106.
Temin, H.M., 1988. Mechanisms of cell killing/cytopathic effects by nonhuman
retroviruses. Rev. Infect. Dis. 10, 399–405.
Todaro, G.J., Arnstein, P., Parks, W.P., Lennette, E.H., Huebner, R.J., 1973. A type-C
virus in human rhabdomyosarcoma cells after inoculation into NIH Swiss mice
treated with antithymocyte serum. Proc. Nat. Acad. Sci. U.S.A. 70, 859–862.
Tomonaga, K., Cofﬁn, J.M., 1999. Structures of endogenous nonecotropic murine
leukemia virus (MLV) long terminal repeats in wild mice: implication for
evolution of MLVs. J. Virol. 73, 4327–4340.
Urisman, A., Molinaro, R.J., Fischer, N., Plummer, S.J., Casey, G., Klein, E.A., Malathi, K.,
Magi-Galluzzi, C., Tubbs, R.R., Ganem, D., Silverman, R.H., DeRisi, J.L., 2006.
Identiﬁcation of a novel gammaretrovirus in prostate tumors of patients homo-
zygous for R462Q oitalic4RNASELo/italic4 variant. PLoS Pathog. 2, e25.
Weller, S.K., Joy, A.E., Temin, H.M., 1980. Correlation between cell killing and
massive second-round superinfection by members of some subgroups of avian
leukosis virus. J. Virol. 33, 494–506.
Whelan, J.T., Kellogg, A., Shewchuk, B.M., Hewan-Lowe, K., Bertrand, F.E., 2009.
Notch-1 signaling is lost in prostate adenocarcinoma and promotes PTEN gene
expression. J. Cell. Biochem. 107, 992–1001.
Yoshimura, F.K., Wang, T., Nanua, S., 2001. Mink cell focus-forming murine
leukemia virus killing of mink cells involves apoptosis and superinfection. J.
Virol. 75, 6007–6015.
Zhang, Y.A., Maitra, A., Hsieh, J.T., Rudin, C.M., Peacock, C.D., Karikari, C., Brekken, R.A.,
Stastny, V., Gao, B., Girard, L., Wistuba, I., Frenkel, E., Minna, J.D., Gazdar, A.F., 2011.
Frequent detection of infectious xenotropic murine leukemia virus (XMLV) in
human cultures established from mouse xenografts. Cancer Biol. Ther. 12, 617–628.
F. Laurent et al. / Virology 456-457 (2014) 28–3838
